Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06505967 · ClinicalTrials.gov registry record · NA
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels
A NA study of NAD+ Levels in the Blood, sponsored by Qualia Life Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06505967: Recruiting NA study of NAD+ Levels in the Blood, sponsored by Qualia Life Sciences.
NCT06505967 is a NA study of NAD+ Levels in the Blood that is actively recruiting participants, run by Qualia Life Sciences. The registered enrollment target is 200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06505967, a NA study of NAD+ Levels in the Blood, is actively recruiting participants, sponsored by Qualia Life Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine if Qualia NAD+ effectively increases NAD+ levels in the blood and to evaluate its safety. Researchers will compare Qualia NAD+ to a placebo (a look-alike substance that contains no active drug) to assess its efficacy in increasing NAD+ levels in the blood. Participants will: Take Qualia NAD+ or a placebo every day for 4 weeks. Undergo blood tests before and after the trial.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Qualia NAD+
Study Locations (1)
California
- Qualia Life Sciences - Carlsbad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2024-09-09 |
| Phase | NA |
What NCT06505967 shows while recruiting
NCT06505967 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 1 condition, with NAD+ Levels in the Blood appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06505967 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06505967 about?
NCT06505967 is a clinical study titled "Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels". The goal of this clinical trial is to determine if Qualia NAD+ effectively increases NAD+ levels in the blood and to evaluate its safety. Researchers will compare Qualia NAD+ to a placebo (a look-alike substance that contains no active drug) to assess its efficacy in increasing NAD+ levels in the b...
What is the current status of trial NCT06505967?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-06-10. Estimated completion is 2024-09-09.
What conditions does trial NCT06505967 study?
This clinical trial studies the following conditions: NAD+ Levels in the Blood.
What interventions are being tested in trial NCT06505967?
The interventions under investigation include: Placebo (OTHER), Qualia NAD+ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06505967?
This trial is sponsored by Qualia Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06505967 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06505967's enrollment target sits among peer trials
200 506th of 2000 higher than 1,434 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI